Utility of Lp-PLA 2 in lipid-lowering therapy

American Journal of Therapeutics

Volumn 19, Issue 2, 2012, Pages 115-120

  Racherla, Sreekanth ^a   Arora, Rohit ^a  

^a The Chicago Medical College   (United States)

Author keywords

Lp PLA 2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; DARAPLADIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; BENZALDEHYDE DERIVATIVE; LOW DENSITY LIPOPROTEIN; OXIME;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME MODIFICATION; HUMAN; MACROPHAGE; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; SECONDARY PREVENTION; SMOOTH MUSCLE FIBER; TREATMENT OUTCOME; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; HYPERLIPIDEMIA; INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATHEROSCLEROSIS; BENZALDEHYDES; BIOLOGICAL MARKERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INFLAMMATION; LIPOPROTEINS, LDL; OXIMES; PLAQUE, ATHEROSCLEROTIC;

EID: 84858797755     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181e70d32     Document Type: Article

References (54)

1. Suckling KE, Macphee CH. Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque. Expert Opin Ther Targets. 2002;6:309-314. (Pubitemid 34662104)
2. Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol. 2009;20:415-420.
3. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008;101:F23-F33.
4. Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoproteinassociated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101: F51-F57.
5. Xu DL, Liu JN, Du YM, et al. The correlation of human serum Lp-PLA2 and hs-CRP and stability of coronary atherosclerotic plaques. Zhonghua Nei Ke Za Zhi. 2009;48: 651-654.
6. Garcia-Garcia HM, Serruys PW. Phospholipase A2 inhibitors. Curr Opin Lipidol. 2009;20:327-332.
7. Hevonoja T, Pentikäinen MO, Hyvönen MT, et al. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim Biophys Acta. 2000;1488:189-210.
8. Lee JY, Min HK, Choi D, et al. Profiling of phospholipids in lipoproteins by multiplexed hollow fiber flow fieldflow fractionation and nanoflow liquid chromatographytandem mass spectrometry. J Chromatogr A. 2010;1217: 1660-1666.
9. Oslakovic C, Jauhiainen M, Ehnholm C, et al. The role of phospholipid transfer protein in lipoprotein-mediated neutralization of the procoagulant effect of anionic liposomes. J Thromb Haemost. 2010;8:766-772.
10. De Keyzer D, Karabina SA, Wei W, et al. Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol. 2009;29:2041-2046.
11. Serruys PW, García-García HM, Buszman P, et al; Integrated Biomarker and Imaging Study-2 Investigators. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172-1182.
12. Hayashi T, Iguchi A. Possibility of the regression of atherosclerosis through the prevention of endothelial senescence by the regulation of nitric oxide and free radical scavengers. Geriatr Gerontol Int. 2010;10:115-130.
13. Batuca JR, Amaral MC, Alves JD. Humoral mechanisms of atherogenesis. Ann N Y Acad Sci. 2009;1173:401-408.
14. Kume N. New oxidized LDL receptors and their functions in atherogenesis. Nippon Ronen Igakkai Zasshi. 2002;39:264-267.
15. Rodríguez G, Mago N, Rosa F. Role of inflammation in atherogenesis. Invest Clin. 2009;50:109-129.
16. Garcia-Garcia HM, Serruys PW. Phospholipase A2 inhibitors. Curr Opin Lipidol. 2009;20:327-332.
17. Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem. 2007;14:3209-3220.
18. Carpenter KL, Challis IR, Arends MJ. Mildly oxidised LDL induces more macrophage death than moderately oxidised LDL: roles of peroxidation, lipoprotein-associated phospholipase A2 and PPARgamma. FEBS Lett. 2003;553:145-150. (Pubitemid 37206341)
19. Carpenter KL, Dennis IF, Challis IR, et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett. 2001;505:357-363. (Pubitemid 32905477)
20. Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10: 36-46.
21. Chepelenko GV. Pathogenesis of atherosclerosis in patients with lipid metabolism disturbances: hypothesis on cholesterol utilization and atheromatous plaque formation. Angiol Sosud Khir. 2003;9:20-25.
22. Kanjuh V, Ostojić M, Lalić N, et al. Low and high density lipoprotein-cholesterol and coronary atherothrombosis. Med Pregl. 2009;62(Suppl 3):7-14.
23. Croons V, De Meyer I, Houten SM, et al. Effect of statins on the viability of macrophages and smooth muscle cells. J Cardiovasc Pharmacol. 2010;55:269-275.
24. Chumachenko PV, Zhdanov VS, Belokoń EV, et al. Antiinflammatory properties of statins in the study of atherosclerotic plaques in the endartectomized coronary arteries. Arkh Patol. 2009;71:23-26.
25. Sumi D, Hayashi T, Thakur NK, et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects-the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis. 2001;155: 347-357. (Pubitemid 32209305)
26. Mohler ER III, Shi Y, Moore J, et al. Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol. Cytometry A. 2009;75(1):75-82.
27. Vasa M, Fichtlscherer S, Adler K, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103:2885-2890. (Pubitemid 32578123)
28. Papathanasiou AI, Lourida ES, Tsironis LD, et al. Shortand long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment. Atherosclerosis. 2008; 196:289-297.
29. McConnell JP, Hoefner DM. Lipoprotein-associated phospholipase A2. Clin Lab Med. 2006;26:679-697.
30. Qiao Z, Ren J, Chen H. Simvastatin reduces expression and activity of lipoprotein-associated phospholipase A(2) in the aorta of hypercholesterolaemic atherosclerotic rabbits. J Int Med Res. 2009;37:1029-1037.
31. Pedersen MW, Koenig W, Christensen JH, et al. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr. 2009;48:1-5.
32. Macphee CH, Nelson JJ, Zalewski A. Lipoproteinassociated phospholipase A2 as a target of therapy [review]. Curr Opin Lipidol. 2005;16:442-446. (Pubitemid 41017628)
33. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007;27: 2236-2243. (Pubitemid 350287255)
34. Garcia-Garcia HM, Serruys PW. Phospholipase A2 inhibitors. Curr Opin Lipidol. 2009;20:327-332.
35. Suckling K. Phospholipase A(2)s: developing drug targets for atherosclerosis. Atherosclerosis. 2010 (E-pub ahead of print).
36. Suckling KE. Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin Investig Drugs. 2009;18: 1425-1430.
37. McCullough PA. Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target? Curr Atheroscler Rep. 2009;11:334-337.
38. Riley RF, Corson MA. Darapladib, a reversible lipoprotein- associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease. IDrugs. 2009;12:648-655.
39. Schmidt EB, Koenig W, Khuseyinova N, et al. Lipoprotein- associated phospholipase A2 concentrations in plasma are associated with the extent of coronary artery disease and correlate to adipose tissue levels of marine n-3 fatty acids. Atherosclerosis. 2008;196:420-424.
40. Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008;101:F23-F33.
41. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol. 2008;101:F41-F50.
42. Raichlin E, McConnell JP, Bae JH, et al. Lipoproteinassociated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. Transplantation. 2008;85:963-968. (Pubitemid 351543158)
43. O'Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy- Thrombolysis In Myocardial Infarction) trial. Circulation. 2006;113:1745-1752. (Pubitemid 43958467)
44. Corsetti JP, Rainwater DL, Moss AJ, et al. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem. 2006;52:1331-1338. (Pubitemid 43956025)
45. Koenig W, Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther. 2009;23: 85-92.
46. Cojocaru IM, Cojocaru M, Ta?na? sescu R, et al. Phospholipase A2 in patients with noncardioembolic ischemic stroke and severe inflammatory reaction. Rom J Intern Med. 2009;47:61-65.
47. Fan P, Liu HW, Wan DH, et al. Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome. Fertil Steril. 2009;92:2054-2057.
48. Fan P, LiuHW,Wang XS, et al. Identification of the G994 T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome. Hum Reprod. 2010;25:1288-1294.
49. Karasawa K. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biophys Acta. 2006;1761: 1359-1372. (Pubitemid 44738709)
50. Ito S, Noguchi E, Shibasaki M, et al. Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma. J Hum Genet. 2002;47:99-101. (Pubitemid 34296663)
51. Suzuki T, Solomon C, Jenny NS, et al. Lipoproteinassociated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail. 2009;2:429-436.
52. Wegner M, Araszkiewicz A, Pioruńska-Miko1ajczak A, et al. The evaluation of IL-12 concentration, PAF-AH, and PLA(2) activity in patients with type 1 diabetes treated with intensive insulin therapy. Clin Biochem. 2009;42: 1621-1627.
53. Hatoum IJ, Hu FB, Nelson JJ, et al. Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes. Diabetes. 2010;59:1239-1243.
54. Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol. 2009;20:415-420.